PL3481964T3 - Biomarkery nieswoistego zapalenia jelita - Google Patents

Biomarkery nieswoistego zapalenia jelita

Info

Publication number
PL3481964T3
PL3481964T3 PL17768220T PL17768220T PL3481964T3 PL 3481964 T3 PL3481964 T3 PL 3481964T3 PL 17768220 T PL17768220 T PL 17768220T PL 17768220 T PL17768220 T PL 17768220T PL 3481964 T3 PL3481964 T3 PL 3481964T3
Authority
PL
Poland
Prior art keywords
biomarkers
inflammatory bowel
bowel disease
disease
inflammatory
Prior art date
Application number
PL17768220T
Other languages
English (en)
Inventor
Paul A. Lyons
Eoin F. Mckinney
Daniele Biasci
James Lee
Original Assignee
Cambridge Enterprise Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Limited filed Critical Cambridge Enterprise Limited
Publication of PL3481964T3 publication Critical patent/PL3481964T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
PL17768220T 2016-07-05 2017-07-05 Biomarkery nieswoistego zapalenia jelita PL3481964T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1611738.4A GB201611738D0 (en) 2016-07-05 2016-07-05 Biomarkers for inflammatory bowel disease
PCT/IB2017/000997 WO2018007872A1 (en) 2016-07-05 2017-07-05 Biomarkers for inflammatory bowel disease
EP17768220.0A EP3481964B1 (en) 2016-07-05 2017-07-05 Biomarkers for inflammatory bowel disease

Publications (1)

Publication Number Publication Date
PL3481964T3 true PL3481964T3 (pl) 2022-04-11

Family

ID=56891052

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17768220T PL3481964T3 (pl) 2016-07-05 2017-07-05 Biomarkery nieswoistego zapalenia jelita

Country Status (15)

Country Link
US (3) US11041206B2 (pl)
EP (1) EP3481964B1 (pl)
JP (2) JP7111630B2 (pl)
KR (1) KR102352847B1 (pl)
CN (1) CN109477145B (pl)
AU (1) AU2017293417B2 (pl)
CA (1) CA3029912A1 (pl)
DK (1) DK3481964T3 (pl)
ES (1) ES2906192T3 (pl)
GB (1) GB201611738D0 (pl)
HU (1) HUE058197T2 (pl)
LT (1) LT3481964T (pl)
PL (1) PL3481964T3 (pl)
PT (1) PT3481964T (pl)
WO (1) WO2018007872A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10515408B2 (en) 2003-08-13 2019-12-24 Bgc Partners, Inc. Systems and methods for bid/offer liquidity spread trading
GB201611738D0 (en) 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
CA3047302C (en) * 2016-12-14 2024-01-02 Tracy WARREN System and methods for developing and using a microbiome-based action component for patient health
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
GB2611267B (en) 2018-10-18 2023-06-28 Smith & Nephew Tissue treatment device
GB201817052D0 (en) 2018-10-19 2018-12-05 Smith & Nephew Tissue treatment device
CN110400603A (zh) * 2019-07-23 2019-11-01 中国石油大学(华东) 基于格局加权的ibd矩阵计算方法
GB201912518D0 (en) 2019-08-30 2019-10-16 Cambridge Entpr Ltd Inflammatory disease prognostics
GB202005867D0 (en) 2020-04-22 2020-06-03 Smith & Nephew Tissue treatment device
GB202100527D0 (en) 2021-01-15 2021-03-03 Smith & Nephew Systems and methods for managing operation of wound dressings or wound treatment devices
CN117295952A (zh) * 2021-03-12 2023-12-26 詹森生物科技公司 用于预测溃疡性结肠炎中治疗响应的方法
CN114517228A (zh) * 2021-12-31 2022-05-20 青岛锐翌精准医学检验有限公司 炎症性肠病标志基因及其应用
CN114645088B (zh) * 2022-04-22 2023-12-15 广东省人民医院 克罗恩病进展风险相关评估基因集、试剂盒、应用和系统
EP4606910A1 (en) * 2024-02-21 2025-08-27 Royal College of Surgeons in Ireland Diagnostic and prognostic methods relating to ulcerative colitis

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412301D0 (en) 2004-06-02 2004-07-07 Diagenic As Product and method
US20070020660A1 (en) * 2005-06-06 2007-01-25 Burczynski Michael E Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
GB0610949D0 (en) * 2006-06-02 2006-07-12 Glaxosmithkline Biolog Sa Method
CA2706729A1 (en) * 2007-11-29 2009-06-11 Genentech, Inc. Gene expression markers for inflammatory bowel disease
KR20110010603A (ko) * 2008-04-02 2011-02-01 메타프로테오믹스, 엘엘씨 치환된 1,3-시클로펜타디온 약독화 내피 염증 및 내피-모노사이트 상호작용
KR100985090B1 (ko) * 2008-05-23 2010-10-04 한국과학기술연구원 크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
US20120003228A1 (en) * 2009-01-20 2012-01-05 Cambridge Enterprise Limited Methods for predicting autoimmune disease risk
EP2419532A1 (en) * 2009-04-17 2012-02-22 Université Libre de Bruxelles Methods and tools for predicting the efficiency of anthracyclines in cancer
EP2272977A1 (en) 2009-07-08 2011-01-12 Universite Libre De Bruxelles Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome
WO2011127219A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
EP2791168A1 (en) 2011-11-23 2014-10-22 Amgen Inc. Methods of treatment using an antibody against interferon gamma
EP2825671A4 (en) 2012-03-13 2015-08-26 Baylor Res Inst EARLY IDENTIFICATION OF A TUBERCULOSE TREATMENT RESPONSE
ES2638971T3 (es) 2012-10-05 2017-10-24 Nestec S.A. Métodos para predecir y monitorizar la cicatrización de la mucosa
WO2014093872A1 (en) 2012-12-13 2014-06-19 Baylor Research Institute Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
KR20150139537A (ko) * 2013-03-15 2015-12-11 더 브로드 인스티튜트, 인코퍼레이티드 수지상 세포의 반응 유전자 발현, 물질의 조성물 및 이의 사용 방법
US10619210B2 (en) * 2014-02-07 2020-04-14 The Johns Hopkins University Predicting response to epigenetic drug therapy
MA39804A (fr) * 2014-03-27 2017-02-01 Hoffmann La Roche Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US10815528B2 (en) * 2014-10-28 2020-10-27 Hummingbird Diagnostics Gmbh MiRNAs as non-invasive biomarkers for inflammatory bowel disease
WO2016138488A2 (en) * 2015-02-26 2016-09-01 The Broad Institute Inc. T cell balance gene expression, compositions of matters and methods of use thereof
US20180305689A1 (en) 2015-04-22 2018-10-25 Mina Therapeutics Limited Sarna compositions and methods of use
US20170003277A1 (en) * 2015-07-01 2017-01-05 Michael Hayden Biological characterization of a glatiramer acetate related drug product using mammalian and human cells
GB201611738D0 (en) 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease

Also Published As

Publication number Publication date
US10640829B2 (en) 2020-05-05
PT3481964T (pt) 2022-02-17
US20190032140A1 (en) 2019-01-31
AU2017293417A1 (en) 2019-02-21
GB201611738D0 (en) 2016-08-17
ES2906192T3 (es) 2022-04-13
KR102352847B1 (ko) 2022-01-17
US10202651B2 (en) 2019-02-12
LT3481964T (lt) 2022-04-11
JP7111630B2 (ja) 2022-08-02
CA3029912A1 (en) 2018-01-11
CN109477145A (zh) 2019-03-15
WO2018007872A1 (en) 2018-01-11
JP2020198884A (ja) 2020-12-17
KR20190025637A (ko) 2019-03-11
US11041206B2 (en) 2021-06-22
WO2018007872A9 (en) 2018-03-15
CN109477145B (zh) 2021-04-09
EP3481964A1 (en) 2019-05-15
HUE058197T2 (hu) 2022-07-28
US20180010189A1 (en) 2018-01-11
JP2019527039A (ja) 2019-09-26
US20180010187A1 (en) 2018-01-11
DK3481964T3 (da) 2022-02-07
AU2017293417B2 (en) 2019-11-14
EP3481964B1 (en) 2021-12-29
NZ750396A (en) 2020-12-18

Similar Documents

Publication Publication Date Title
HUE058197T2 (hu) Biomarkerek gyulladásos bélbetegséghez
IL276516A (en) Methods for diagnosing and treating inflammatory bowel disease
GB2566681B (en) Biomarker
GB201420908D0 (en) Biomarkers
EP3201622A4 (en) Markers for inflammatory bowel disease
GB201614455D0 (en) Biomarkers
GB201401603D0 (en) Biomarkers
EP3284830A4 (en) Biomarker for mental disease
SG11201706686YA (en) Methods for determining resist deformation
SG10202007262PA (en) Copanlisib biomarkers
SG10202007322PA (en) Copanlisib biomarkers
IL256198A (en) Biomarkers for disease states for kidney disease
ZA202001821B (en) Biomarker
DK3198034T3 (da) Biomarkører for cervixcancer
SG10201800570RA (en) Biomarkers for assessing hiv
GB201705044D0 (en) Biomarker
PL3289355T3 (pl) Sposoby wykrywania chorób nerek
GB201500729D0 (en) Novel Biomarkers
GB201306339D0 (en) Biomarkers for prognosis
GB201512133D0 (en) Biomarkers
HK40007518A (en) Biomarkers for inflammatory bowel disease
LU92499B1 (en) Mirna 320a as biomarker for inflammatory bowel disease
ZA201700644B (en) Maize biomarkers for disease resistance
GB201613912D0 (en) Predictive biomarker
GB201521446D0 (en) Biomarker